Form 4: Applied DNA Sciences CFO Acquires 18,691 Shares

Applied DNA Sciences' CFO, Beth Jantzen, acquired 18,691 shares of common stock as restricted stock units, vesting 90 days from the grant date.

Summary

• Beth Jantzen, Chief Financial Officer of Applied DNA Sciences Inc. (BNBX), acquired 18,691 shares of common stock.
• The transaction occurred on October 17, 2025, with a reported price of $0 per share, indicating a grant of restricted stock units.
• Following this acquisition, Beth Jantzen beneficially owns a total of 18,694 shares of common stock.
• The acquired restricted stock units will vest 100% upon 90 days from the date of grant.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive like the CFO is generally viewed positively as it aligns management's interests with those of shareholders. While it's a compensation grant rather than an open market purchase, it still indicates commitment.

Positives

• Chief Financial Officer Beth Jantzen increased her direct ownership in Applied DNA Sciences by acquiring 18,691 shares, demonstrating alignment with shareholder interests.
• The acquisition, likely a compensation grant, indicates continued commitment of key management to the company.

Future Outlook

The acquired restricted stock units are scheduled to vest 100% approximately 90 days from the grant date of October 17, 2025, indicating a future increase in the CFO's vested equity.

Industry Context

This insider transaction is a routine compensation event for a public company executive and does not directly reflect broader industry trends, though it signifies continued executive engagement within the biotechnology or life sciences sector where Applied DNA Sciences operates.

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership can signal confidence and better align management incentives with shareholder value.
• Employees: No direct impact mentioned.
• Management: Beth Jantzen's equity stake increases, strengthening her financial ties to the company's performance.

Next Steps

• The 18,691 restricted stock units will vest 100% approximately 90 days from the grant date of October 17, 2025.

Key Dates

Keywords

Applied DNA Sciences, BNBX, Beth Jantzen, CFO, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, Equity Compensation